Dade Behring Marburg Gmbh

Bernhard Giesendorf

Hans-Peter Hauser

Markus Eickmann

Klaus Radsak

Dorothee Gicklhorn

virus (VZV) inimunoreactive protein VP26 and its diagnostic use are described. The invention relates to immunoreactive peptides which are homologous with the region of amino acid positions 12 to 235 (SEQ ID NO: 7) of thevirus protein VP26, to nucleic acids which encode these peptides and to the use of the peptides or nucleic acids for diagnosing an infection withvirus.

Varicella zoster virus (VZV) immunoreactive protein VP26 and its diagnostic use

The present invention relates to immunoreactive peptides that are homologous with the region encompassing amino acid positions 450 to 655 of glycoprotein II of varicella zoster virus. In this context, preference is given to those peptides corresponding to segments of amino acids 505 to 647, 517 to 597, 535 to 584 or 545 to 582. The immunoreactive peptides are useful for methods of diagnosing varicella zoster virus infection.

Immunoreactive regions of glycoprotein gpII of varicella zoster virus (VZV)

Immunoreactive regions of glycoprotein GPII of varicella zoster virus

virus (VZV) immunoreactive protein VP26 and its diagnostic use are described. The invention relates to immunoreactive peptides which are homologous with the region of amino acid positions 12 to 235 of the,virus protein VP26, to nucleic acids which encode these peptides and to the use of the peptides or nucleic acids for diagnosing an infection with,virus.

The use of calcium salts, magnesium salts or combination thereof in immunochemical methods for the determination of an analyte in a sample. These salts increase the specificity of such determinations, in particular, the background signal being reduced by addition of these salts in solid phase immunochemical methods.

Growing community of inventors

Michelbach, Germany

Bernhard Giesendorf